XOMA (XOMA +7.1%) says its partner, Servier has begun phase 3 clinical trials of of Gevokizumab in several European countries. The study is intended to test the efficacy and safety of the drug in the treatment of patients with Behçet's Disease uveitis.
From other sites
at CNBC.com (Mar 5, 2014)
at CNBC.com (Jan 10, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs